Alpha Teknova, Inc. (TKNO): Capital Expenditures
$1.15M
Year ended 2025-12-31
$1.08M
Trailing 12 months to 2026-06-30
-65.6%
3-year compound annual growth
-26.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.15M | +2.0% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $1.12M | -85.8% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $7.93M | -71.8% | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | $28.15M | +41.6% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $19.88M | +263.6% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $5.47M | n/a | 2022-03-18, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $1.15M | +2.0% |
| Immucell Corp (ICCC) | 2025-12-31 | $1.25M | +168.5% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $1.13M | -80.5% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $16.0K | -56.8% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $3.19M | +517.2% |
| Neogen Corp (NEOG) | 2026-05-31 | $51.30M | -51.0% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $89.6K | -67.7% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $2.71M | +41.4% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $188.20M | -3.5% |
Compare TKNO, ICCC, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗